Background
Phase III RCT (ECOG E4201). 74 patients with locally advanced, unresectable pancreatic cancer. Randomized to gemcitabine alone or gemcitabine + radiation. Trial was closed early due to poor accrual (planned n=316). This is the only phase III trial showing OS benefit for adding RT to gemcitabine in locally advanced pancreatic cancer.
Interventions and follow up
Arm A: Gemcitabine 600 mg/m² twice weekly during RT (50.4 Gy in 28 fractions), then gemcitabine 1,000 mg/m² weekly × 3 every 4 weeks × 5 cycle
Arm B: Gemcitabine 1,000 mg/m² weekly × 3 every 4 weeks × 7 cycle
Primary endpoint: Overall survival
mFollow up: NR
Arm B: Gemcitabine 1,000 mg/m² weekly × 3 every 4 weeks × 7 cycle
Primary endpoint: Overall survival
mFollow up: NR
Results
mOS: 11.1 months (gemcitabine + RT) vs 9.2 months (gemcitabine alone), HR 0.79, P=.017
1-yr OS: 50% vs 32%
1-yr OS: 50% vs 32%
Adverse events
Main adverse events: Grade ≥4 toxicity: 41% (gem+RT) vs 9% (gem alone). Grade ≥3 fatigue: 35% vs 16%. Grade ≥3 nausea/vomiting: 18% vs 6%.
Conclusions
Gemcitabine-based CRT showed a statistically significant OS benefit over gemcitabine alone in locally advanced pancreatic cancer (11.1 vs 9.2 months, P=.017), but with substantially higher toxicity. This was the only phase III trial to show benefit for adding RT in LAPC.
Key Limitations
Key Limitations: Closed early due to poor accrual (74 of planned 316 patients) — highly underpowered and potentially unreliable. The modest absolute OS benefit (1.9 months) is of limited clinical significance. High grade ≥4 toxicity (41%) substantially limits clinical utility. CRT was delivered concurrently with a suboptimal gemcitabine dose, not the full 1,000 mg/m² that is standard. The LAP07 trial (Hammel 2016) subsequently failed to show OS benefit for CRT after induction chemotherapy in LAPC.
Clinical Context
ECOG E4201's results conflict with LAP07 (no OS benefit for CRT after induction chemo in LAPC). Modern practice for LAPC emphasizes induction chemotherapy with FOLFIRINOX or gemcitabine/nab-paclitaxel first, with CRT reserved for patients without progression to consolidate local control in selected cases.
References
References: Loehrer PJ et al, J Clin Oncol 2011 (ECOG E4201)